Overview
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Description
Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.
Eligibility
Inclusion Criteria:
- Patients with pathologically confirmed pancreatic cancer (primary)
- Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
- The postoperative survival time was at least 6 weeks
Exclusion Criteria:
- No surgery was performed, or only palliative surgery/ biopsy was performed
- Patients who underwent emergency hemodialysis or plasma exchange after surgery
- History of gout or long-term urate-lowering therapy, such as allopurinol
- Patients are missing follow-up data
- Hydrochlorothiazide and furosemide were used
- Chronic kidney disease
- Oncolytic syndrome
- Hemolytic anemia
- Lead poisoning
- Hyperparathyroidism
- Hypothyroidism
- A tyrosinase inhibitor was used
- Patients with nonpancreatic primary tumors
- Pregnant or postpartum women.